Global Hospital-Acquired Infection Therapeutics Market $6.5 Billion by 2029

The global market for hospital-acquired infection therapeutics expected to reach $6.5 billion by 2029, growing at a CAGR of 5.0% over the forecast period, driven by increasing prevalence of hospital-acquired infections and rising demand for anti-infective drugs worldwide.

• An increasing number of patients are intermittently exposed to the healthcare environment and may become colonized or infected with healthcare-associated pathogens without ever being admitted to the hospital and thus may acquire hospital-associated infections before admission.
  • Other factors supporting growth of hospital infection therapy market include high incidence of neonatal infections in neonatal care units of hospitals and lack of trained staff in developing and underdeveloped regions of the world.

Hospital-acquired or hospital-associated infections (HAIs) or nosocomial infections are infections that occur after hospital admission and that were neither present nor incubating at the time of admission. 

These healthcare-associated infections (HCAIs) include central line-associated bloodstream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), and ventilator-associated pneumonia (VAP). Infections may also occur at surgery sites, known as surgical site infections (SSI).

• The hospital-acquired infections (HAIs) are one of the most common preventable complications of hospitalized patients, and therefore are frequently used as indicators of the quality of patient care.
  • The most important HAIs are associated with significant mortality, morbidities and increasing healthcare cost.
  • Several species of bacteria and fungi cause HCAI; the most widely publicized is the hospital ‘superbug’ MRSA, a common cause of bacteraemia and septicaemia.
    • Bloodstream infections, followed by pneumonia and urinary tract infections are the most infections in children, urinary tract infections are the most common hospital-acquired infections in adults. 

The global hospital-acquired infection therapeutics market report estimates the market size ($million 2019 to 2029), market share, growth trends, and forecast (CAGR% 2023 to 2029).  

The global market for HAI therapeutics segmented by product (antibacterial drugs, antifungal drugs and antiviral drugs), clinical pipeline analysis (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), indication (blood stream infections, gastrointestinal disorders, hospital-acquired pneumonia, surgical site Infections, urinary tract Infections, other hospital infections), and geography.

• Based on the products, the antibacterial drugs segment accounted for the largest share of total hospital-acquired infection therapeutics market, along with the fastest CAGR throughout the forecast period.
  • Antibacterial drugs are the most widely used drugs to treat infections that have been acquired within a healthcare setting.
    • Most of these infections (hospital-acquired pneumonia, C. difficile associated diarrhea, urinary tract infections, bloodstream infections, surgical site infections) require antibacterial treatments.
• In terms of indications, the hospital-acquired pneumonia (HAP) or nosocomial pneumonia or healthcare associated pneumonia (HCAP) or ventilator-associated pneumonia (VAP), segment dominated the total hospital-acquired infection therapeutics market.
  • HAP is one of the most common causes of hospital infections worldwide, often caused by drug-resistant Streptococcus pneumoniae.
  • Urinary tract infections (UTIs), being the leading hospital infections, account for almost 40% of the overall hospital infections worldwide.
    • UTIs including catheter-associated UTIs (CAUTIs) are forecast to grow at the highest rate during the forecast period.
      • These infections are cause mainly by E. coli, Candida sp., Enterococci, Pseudomonas aeruginosa, Klebsiella sp., and Enterobacter sp.

The global market for hospital-acquired infection therapeutics research report is divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

• By geography, the North America region dominated the hospital-acquired infection therapeutics market, owing to high prevalence of various hospital infections, increasing demand for HAI therapeutics and rising number of multi-drug resistant (MDR) microorganisms in the developed region.
  • On the other hand, the Asia Pacific hospital-acquired infection therapeutics market predicted to grow at the fastest rate, attributed to rising incidences of hospital infections, improved healthcare facilities, increasing awareness for HAI therapeutics in the developing region

The global HAI therapeutics market report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

Major competitors operating in the global HAI therapeutics market and included in this report are Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi S.A.

• Product
  • Antibacterial Drugs
  • Antifungal Drugs
  • Antiviral Drugs
• Pipeline Analysis
  • Amikacin Inhale
  • CAZ AVI (Ceftazidime/Avibactum)
  • Ceftolozane/Tazobactam
  • Dalvance (Dalbavancin)
  • Delafloxacin (RX-3341)
  • Eravacycline (TP-434)
  • MK-3415A
  • Oritavancin
  • Plazomicin
  • Surotomycin (CB-315)
  • Tedizolid (TR-701)
• Indication
  • Bloodstream Infections
  • Gastrointestinal Disorders
  • Hospital-Acquired Pneumonia (HAP)
  • Surgical Site Infections (SSIs)
  • Urinary Tract Infections (UTIs)
  • Other Hospital Infections
• Geography
  • North America (U.S., Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
  • Asia Pacific (Japan, China, India, Rest of APAC)
  • Latin America (Brazil, Mexico, Rest of LA)
  • Rest of the World
• Company Profiles
  • Actavis plc
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cubist Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi S.A .

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/hospital-infection-therapeutics-market/

Related publications:

• Global Hospital-Acquired Infection Diagnostics Market $5.1 Billion by 2029
• Hospital-Acquired Infection Therapeutics Market by Product (Antibacterial, Antifungal and Antiviral Drugs), Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), and Indications (Blood Stream Infections, Gastrointestinal Disorders, HAP, SSIs, UTIs) and Forecast 2023-2029
• Hospital-Acquired Pneumonia Drugs Market by Clinical Phase [Amikacin Inhale, Ceftazidime (Avibactum), Ceftolozane (Tazobactam), Plazomicin, Synflorix Vaccine, and Tedizolid Phosphate] and Forecast 2023-2029
• Hospital-Acquired Disease Testing Market by Test [Blood Stream Associated Infection, Methicillin-resistant Staphylococcus aureus Infection, Hospital-Acquired Pneumonia, Surgical Associated Infection, Urinary Tract Infection, Others (Gastroenteritis, Puerperal Fever)] and Forecast 2023-2029
• Global Urinary Catheters Market $5.1 Billion by 2029